News | Cardiovascular Business | October 23, 2023

Mindray Expands Cardiac Biomarker Portfolio with Launch of New Assays

Global medical devices and solutions provider Mindray has announced the introduction and global launch of two new high-sensitivity troponin I (hs-cTnI) and NT-proBNP cardiac biomarkers. The additions enhance Mindray's diverse portfolio of cardiac biomarkers for diagnosing and managing cardiovascular diseases (CVDs), according to a written statement issued recently on the launch.

Mindray has announced the introduction and global launch of two new high-sensitivity troponin I (hs-cTnI) and NT-proBNP cardiac biomarkers. The additions enhance Mindray's diverse portfolio of cardiac biomarkers for diagnosing and managing cardiovascular diseases (CVDs), according to a written statement issued by the global medical devices and solutions provider. Image courtesy: Mindray


October 23, 2030 — Global medical devices and solutions provider Mindray has announced the introduction and global launch of two new high-sensitivity troponin I (hs-cTnI) and NT-proBNP cardiac biomarkers. The additions enhance Mindray's diverse portfolio of cardiac biomarkers for diagnosing and managing cardiovascular diseases (CVDs), according to a written statement issued recently on the launch, which noted the new offerings are the result of Mindray's ongoing efforts in developing advanced chemiluminescence immunoassay products.

While CVDs are the leading cause of death worldwide, the company reinforced that early detection is key in saving lives. The statement further offered that guidelines recommend the use of cTnl and NT-proBNP as essential biomarkers for suspected Acute Coronary Syndrome (ACS) and heart failure. They enable early screening, risk stratification, rapid diagnosis, and therapeutic monitoring, aiding timely life-saving clinical decisions.

Mindray's hs-cTnI and NT-proBNP assays are the outcome of a fruitful collaboration between Mindray and HyTest, a prominent global provider of antibodies and antigens acquired by Mindray in 2021. The statement also reported that HyTest, renowned for their cardiac biomarker expertise, had their cardiac troponin complex material selected as the international troponin standard by AACC in 2004.

Mindray's announcement offered the following details: The hs-cTnI assay far surpasses the minimum requirements for hs-cTn by achieving a remarkable 93% detection rate between LoD and 99th URL and an imprecision CV below 5% at the 99th URL. This demonstrates the assay's exceptional sensitivity, precision, and reliability in detecting myocardial injury. Furthermore, a 0-2h diagnostic algorithm study conducted at the Hennepin Healthcare Research Institute further supports its effectiveness in accurately diagnosing and managing cardiac conditions within this crucial timeframe.

NT-proBNP is an established cardiac marker for heart failure and its management. Mindray's NT-proBNP assay demonstrates high precision with a CV of ≤5% and effectively minimizes interference from 55 common medications for heart diseases, making it a reliable tool for heart failure detection and management.

“Through integrating HyTest's pioneering antibodies and research on cardiac biomarkers with Mindray's advanced reagent technology and platform, we will deliver more reliable solutions that bring improved patient outcomes in the field of cardiovascular diseases and beyond,” said Mindray IVD Chief Scientific Officer, Dr. Jianwen He.

The company also reported that in catering to the diverse needs of its customers, it has integrated hs-cTnI, NT-proBNP, BNP, TnI, CK-MB, and MYO into its comprehensive cardiac total solution for clinical application and management, adding that the panel is designed for easy usability across all of Mindray’s immunoassay platforms.

More information: www.mindray.com


Related Content

News | Cardiovascular Business

February 28, 2024 — Royal Philips has announced the proposal to appoint Charlotte Hanneman as member of the Board of ...

Home February 28, 2024
Home
News | Cardiovascular Business

February 22, 2024 — Ismail El-Hamamsy, MD, PhD, Director of Aortic Surgery for the Mount Sinai Health System and the ...

Home February 22, 2024
Home
Feature | Cardiovascular Business | By Melinda Taschetta-Millane

It is a new year with lots of new content! Here is a look at the most-read content during the month of January on ...

Home February 01, 2024
Home
Feature | Cardiovascular Business

Did you know that Diagnostic and Interventional Cardiology (DAIC) maintains more than 40 comparison charts of product ...

Home January 29, 2024
Home
News | Cardiovascular Business

January 24, 2024 — Medtronic announced the recent appointment of Simona Zannetti, MD, as the General Manager of its ...

Home January 24, 2024
Home
News | Cardiovascular Business

January 22, 2024 — The American College of Cardiology is again urging members of Congress to retroactively eliminate the ...

Home January 22, 2024
Home
News | Cardiovascular Business

January 22, 2024 — A physician-scientist from Massachusetts researching whether chemicals naturally occurring in foods ...

Home January 22, 2024
Home
News | Cardiovascular Business

January 22, 2024 — Asklepios BioPharmaceutical, Inc. (AskBio), a gene therapy company wholly owned and independently ...

Home January 22, 2024
Home
News | Cardiovascular Business

January 12, 2024 — The Heart Surgeon’s Cookbook is the brainchild of New York-based Cardiovascular and Thoracic Surgeon ...

Home January 12, 2024
Home
News | Cardiovascular Business

January 8, 2024 — GE HealthCare announced it has entered into an agreement to acquire MIM Software, a global provider of ...

Home January 08, 2024
Home
Subscribe Now